The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Michel Vounatsos net worth and biography

Michel Vounatsos Biography and Net Worth

CEO of Biogen

Michel Vounatsos is Chief Executive Officer at Biogen and has served as a director since January 2017. As CEO, his time has been spent strategically bolstering Biogen as a worldwide pioneer in neuroscience and adjacent therapeutic areas, positioning the company for long-term growth through a multi-franchise portfolio.

He brings comprehensive global leadership expertise resulting from decades of service as an executive in the pharmaceutical industry, as well as a unique academic perspective from his time studying both medicine and business. He joined Biogen as Executive Vice President & Chief Commercial Officer in April 2016, holding that role until his promotion to CEO. Prior to that, he had a 20-year career at Merck, where he worked in diverse markets globally, including China, France, and Poland. His last role at Merck was President, Primary Care and Customer Centricity in the United States. During his tenure at Merck, he helped transform its go-to-market model and further expanded its business in mature and emerging markets. Previously, he held management positions at Ciba-Geigy AG, a pharmaceutical company.

He is a director of PerkinElmer, Inc., a global scientific technology and life science research company. He serves on the advisory board of China’s Tsinghua University School of Pharmaceutical Sciences; the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, France; and as a member of the MIT Presidential CEO Advisory Board. He is on the board of directors at the U.K.’s Early Detection of Neurodegenerative Diseases (EDoN). Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Université Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

What is Michel Vounatsos' net worth?: The estimated net worth of Michel Vounatsos is at least $714,627.13 as of December 29th, 2017. Mr. Vounatsos owns 4,879 shares of Biogen stock worth more than $714,627 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Vounatsos may own. Learn More about Michel Vounatsos' net worth.
How do I contact Michel Vounatsos?: The corporate mailing address for Mr. Vounatsos and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Michel Vounatsos' contact information.
Has Michel Vounatsos been buying or selling shares of Biogen?: Michel Vounatsos has not been actively trading shares of Biogen within the last three months. Most recently, on Monday, November 30th, Michel Vounatsos bought 3,100 shares of Biogen stock. The stock was acquired at an average cost of $241.31 per share, with a total value of $748,061.00. Learn More on Michel Vounatsos' trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 1,313 shares worth more than $290,048.92. The most recent insider tranaction occured on September, 3rd when insider Priya Singhal sold 431 shares worth more than $88,018.82. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 9/3/2024.

Michel Vounatsos Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2020	Buy	3,100	$241.31	$748,061.00
5/1/2019	Buy	4,351	$231.48	$1,007,169.48
12/29/2017	Buy	780	$320.55	$250,029.00
12/29/2017	Buy	780	$320.55	$250,029.00	4,879
5/1/2017	Buy	1,402	$271.35	$380,432.70
2/27/2017	Buy	1,333	$285.39	$380,424.87

Michel Vounatsos Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $146.47

$145.07

$147.85

50 Day Range

MA: $167.48

$146.47

$191.56

2 Week Range

Now: $146.47

$145.07

$268.30

Volume

5,775,622 shs

Average Volume

1,216,867 shs

Market Capitalization

$21.34 billion

P/E Ratio

13.23

Dividend Yield

N/A

Beta

N/A

Vladimir Lenin was right…

From Porter & Company | Ad